Merck Serono Focuses On China For Expansion
This article was originally published in PharmAsia News
Executive Summary
Merck Group's Chairman of the Executive Board Karl-Ludwig Kley declared that the company will expand its investment in China and other Asian countries in the near future. China has been one of Merck's top 10 markets for antitumor drug Erbitux (cetuximab), with sales growing over 70 percent this year. However, the company thinks there is still potential for greater performance. Merck's pharmaceutical business in 2007 hit €4.88 billion, of which Serono's prescription drugs contributed €4.46 billion. Serono concentrates on oncology, neurodegenerative disease, autoimmune and inflammatory disease, as well as infertility and endocrine disease. Merck hopes that Serono will become one of the top 15 pharmaceutical companies in China before 2012. (Click here for more - Chinese Language)
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.